Dennis D. Kim - Apr 13, 2023 Form 4 Insider Report for CymaBay Therapeutics, Inc. (CBAY)

Role
Chief Medical Officer
Signature
/s/ Paul Quinlan, as attorney-in-fact for Dennis D. Kim
Stock symbol
CBAY
Transactions as of
Apr 13, 2023
Transactions value $
-$616,016
Form type
4
Date filed
4/17/2023, 07:24 PM
Previous filing
Mar 30, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CBAY Common Stock Options Exercise $34K +7.78K +38.91% $4.37 27.8K Apr 13, 2023 Direct
transaction CBAY Common Stock Sale -$69.9K -7.78K -28.01% $8.98 20K Apr 13, 2023 Direct F1
transaction CBAY Common Stock Options Exercise $490K +112K +561.1% $4.37 132K Apr 17, 2023 Direct
transaction CBAY Common Stock Sale -$1.07M -112K -84.87% $9.54 20K Apr 17, 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CBAY Employee Stock Option (right to buy) Options Exercise $0 -7.78K -2.68% $0.00 282K Apr 13, 2023 Common Stock 7.78K $4.37 Direct F3
transaction CBAY Employee Stock Option (right to buy) Options Exercise $0 -112K -39.78% $0.00 170K Apr 17, 2023 Common Stock 112K $4.37 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.98 to $8.985, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.30 to $9.80, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The original option grant vested as to 1/4 of the underlying shares on May 17, 2022 and vests as to 1/48 of the underlying shares monthly thereafter.